Del. Jury Says NanoString Owes $31M In 10x Patent Spat

By Lauren Berg · November 17, 2023, 11:41 PM EST

A Delaware federal jury on Friday determined that Seattle-based NanoString Technologies Inc. willfully infringed several gene technology patents exclusively licensed to 10x Genomics and awarded more than $31 million in damages,...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Verdict

Case Information

Case Title

10X Genomics, Inc. et al v. Brucker Spatial Biology Inc. et al

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

May 06, 2021

Recent Articles By Lauren

November 15, 2024
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping
November 12, 2024
J&J Says HHS Is Thwarting Transparency Of Drug Discounts
October 30, 2024
FDA Didn't Flub Approval In Orphan Drug Case, DC Court Says
October 18, 2024
Oklahoma Brings Title X Funding Cut Fight To Justices
October 11, 2024
Feds Target Ill. Hospital CEO As $19M Theft Probe Widens
October 11, 2024
Quinn Emanuel Gets Trimmed $92M Fee In ACA Cases
September 30, 2024
Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
September 30, 2024
Bristol-Myers Beats Celgene Investors' Drug Delay Suit
September 27, 2024
9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule
August 30, 2024
McKesson, Others To Pay Benefit Plans $300M In Opioid Deal